Evidence map›Paper›PMID 27314342›Full record

ReviewInternational journal of molecular sciences2016

A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence.

Jonathan L Temple, Paul Cordero, Jiawei Li, Vi Nguyen, Jude A Oben

Registry-linked trialAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06348706 (Effect of Dipeptidyl Peptidase- 4 Inhibitors Supplementation on Non-Alcoholic Steatohepatitis in Adolescents With Type 1 Diabetes Mellitus), which is not on this map. Cited by 84 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06348706 phase3completednot on this mapstarted 2022, after this paper: background citation

Effect of Dipeptidyl Peptidase- 4 Inhibitors Supplementation on Non-Alcoholic Steatohepatitis in Adolescents With Type 1 Diabetes Mellitus

TypeinterventionalSponsorAin Shams UniversityRan2022 to 2024Enrolled60ConditionsDiabetes Mellitus, Type 1, NASHArmsDipeptidyl peptidase 4 (DPP-4) inhibitor
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. MASLD In Children - A Distinct Phenotype?Current obesity reports · 2026
    Review
  8. Article
  9. The Ovary-Liver Axis: Molecular Science and Epidemiology.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Nutrients · 2022
    Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonathan L TempleFaculty of Life Sciences and Medicine, King's College London, Strand, London WC2R 2LS, UK. jonathan.temple@kcl.ac.uk.
Paul CorderoInstitute for Liver and Digestive Health, University College London, Rowland Hill Street, London NW3 2PF, UK. paul.sanchez@ucl.ac.uk.
Jiawei LiInstitute for Liver and Digestive Health, University College London, Rowland Hill Street, London NW3 2PF, UK. jiawei.li.10@ucl.ac.uk.
Vi NguyenInstitute for Liver and Digestive Health, University College London, Rowland Hill Street, London NW3 2PF, UK. v.nguyen@ucl.ac.uk.
Jude A ObenInstitute for Liver and Digestive Health, University College London, Rowland Hill Street, London NW3 2PF, UK. j.oben@ucl.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is now the most prevalent form of chronic liver disease, affecting 10%-20% of the general paediatric population. Within the next 10 years it is expected to become the leading cause of liver pathology, liver failure and indication for liver transplantation in childhood and adolescence in the Western world. While our understanding of the pathophysiological mechanisms underlying this disease remains limited, it is thought to be the hepatic manifestation of more widespread metabolic dysfunction and is strongly associated with a number of metabolic risk factors, including insulin resistance, dyslipidaemia, cardiovascular disease and, most significantly, obesity. Despite this, "paediatric" NAFLD remains under-studied, under-recognised and, potentially, undermanaged. This article will explore and evaluate our current understanding of NAFLD in childhood and adolescence and how it differs from adult NAFLD, in terms of its epidemiology, pathophysiology, natural history, diagnosis and clinical management. Given the current absence of definitive radiological and histopathological diagnostic tests, maintenance of a high clinical suspicion by all members of the multidisciplinary team in primary and specialist care settings remains the most potent of diagnostic tools, enabling early diagnosis and appropriate therapeutic intervention.

Indexed as

AdolescentAge FactorsCarcinoma, HepatocellularChildDisease ManagementHumansLiver CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsadolescentchildrenNAFLDobesitysteatosis

Identifiers

PMID27314342
PMCPMC4926480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.